iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences.

iBio to Participate in Upcoming Investor Conferences

Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

–  The sale of the facility eliminates $13.2M of secured debt – –  Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapeutics, today announced the closing of the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5 million. Following the issuance of pre-funded warrants having a value of $4.5 million to the lender, Woodforest National Bank, iBio and its wholly owned subsidiary, iBio CDMO LLC, has met all of the conditions of the settlement agreement releasing the Company and its subsidiary of all obligations with respect to the debt secured by the Property.

iBio Closes Sale of Manufacturing Facility in Texas

BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Innovage Holding Corp

Moderna

The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble

Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.

iBio stock nearly tripled on Wednesday: here's why

iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.

iBio partners with AstralBio to develop obesity treatments using AI-driven platform

iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new initiative. Specifically, the firm announced that its AI drug discovery platform would be used to develop obesity treatments.

Why Is iBio (IBIO) Stock Up 125% Today?

– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement agent fees and offering expenses. The fully subscribed PIPE financing included participation from ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional and accredited investors.

iBio Announces $15.0 Million Private Placement

– Deal includes $1 million upfront and potential future milestone payments – – iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), pursuant to which Otsuka acquired iBio's assets related to its early-stage programmed cell death protein 1 (“PD-1” ) agonist program.

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - - VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -

iBio Announces Participation in 23rd Annual PepTalk Conference

Allovir, Inc.

GRI Bio Inc

Vyne Therapeutics

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated November 1, 2021 (the “Agreement”), extending the Agreement's maturity date from December 31, 2023 to the earlier March 29, 2024, or the acceleration of maturity of the term loan in accordance with the Credit Agreement. “We are pleased to have worked constructively with Woodforest to execute this amendment and extension of the maturity date of our existing Credit Agreement,” said Martin Brenner, DVM, Ph.D.

iBio Amends and Extends Maturity of Credit Agreement

Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IBIO stock for $2 each.

Why Is iBio (IBIO) Stock Down 41% Today?

BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The Series C Warrants to purchase up to an aggregate of 2,250,000 shares of common stock and Series D Warrants to purchase up to an aggregate of 2,250,000 shares of common stock will have an exercise price of $2.00 per share, will be exercisable immediately following the date of issuance and will expire two years and five years from the original issuance date, respectively.

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company's common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708.

iBio Announces Reverse Stock Split

- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

– No new securities are being registered under the Post-Effective Amendment – – No new securities are being registered under the Post-Effective Amendment –

iBio Explains Recent Filing of Registration Statement

Centene

Cosmos Holdings

The healthcare industry has historically provided significant returns to investors. And, it is currently boasting a compounding annual growth rate prediction of 10.4% until 2027.

Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done

BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023.

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

– Extends maturity date to December 31, 2023 – – Allows time to close pending sale of CDMO facility – BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and Woodforest National Bank (“Woodforest”) have entered into a sixth amendment (the “Amendment”) to their November 1, 2021 credit agreement (the “Credit Agreement”), extending the Agreement's maturity date from November 1, 2023 to the earlier of December 31, 2023 or the acceleration of maturity of the term loan in accordance with the Credit Agreement.

iBio Announces Amendment to Credit Agreement with Woodforest

– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets –

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer, effective immediately.

News for iBio Stock (IBIO)